Free Trial

Takeda Pharmaceutical (TAK) Financials

Takeda Pharmaceutical logo
$15.50 +0.19 (+1.26%)
Closing price 08/22/2025 03:59 PM Eastern
Extended Trading
$15.01 -0.49 (-3.18%)
As of 08/22/2025 06:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Takeda Pharmaceutical

Annual Income Statements for Takeda Pharmaceutical

This table shows Takeda Pharmaceutical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders
1,032 1,758 1,214 413 3,399 1,894 2,388 953 720
Consolidated Net Income / (Loss)
1,037 1,757 1,213 413 3,401 1,895 2,388 954 721
Net Income / (Loss) Continuing Operations
1,037 1,757 1,213 413 3,401 1,895 2,388 954 721
Total Pre-Tax Income
1,287 2,044 1,146 -567 3,311 2,492 2,826 349 1,168
Total Operating Income
1,399 2,275 2,135 937 4,604 3,795 3,695 1,416 2,285
Total Gross Profit
10,534 11,992 12,982 20,543 19,919 20,275 20,967 18,761 20,022
Total Revenue
15,550 16,658 18,835 30,712 28,908 29,389 30,339 28,196 30,564
Operating Revenue
15,550 16,658 18,835 30,712 28,908 29,389 30,339 28,196 30,564
Total Cost of Revenue
5,016 4,666 5,853 10,169 8,988 9,114 9,372 9,434 10,542
Operating Cost of Revenue
5,016 4,666 5,853 10,169 8,988 9,114 9,372 9,434 10,542
Total Operating Expenses
9,134 9,717 10,847 19,606 15,316 16,480 17,272 17,346 17,737
Selling, General & Admin Expense
5,558 5,910 6,445 9,002 7,916 7,299 7,513 6,969 7,370
Marketing Expense
1,407 1,149 1,604 4,250 3,814 3,894 4,086 4,312 4,291
Research & Development Expense
2,804 3,062 3,308 4,595 4,121 4,332 4,771 4,827 4,871
Other Operating Expenses / (Income)
-1,289 -1,594 -1,436 -562 -2,875 -355 -192 -128 -175
Impairment Charge
654 1,191 926 2,321 2,340 1,310 1,094 1,366 1,379
Total Other Income / (Expense), net
-112 -231 -989 -1,504 -1,293 -1,303 -869 -1,067 -1,117
Interest Expense
209 300 748 1,540 2,248 1,372 1,278 1,454 1,401
Interest & Investment Income
110 372 151 260 954 195 474 344 311
Other Income / (Expense), net
-14 -303 -392 -224 0.69 -127 -65 43 -27
Income Tax Expense
250 287 -67 -980 -90 596 437 -604 447
Net Income / (Loss) Attributable to Noncontrolling Interest
-5.14 1.67 1.01 -0.46 -1.50 -0.88 -0.16 -0.86 -1.43
Basic Earnings per Share
$147.15 $239.35 $140.61 $28.41 $240.72 $1.21 $1.54 $0.61 $0.46
Weighted Average Basic Shares Outstanding
- - 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B
Diluted Earnings per Share
$146.26 $237.56 $139.82 $28.25 $238.96 $1.20 $1.52 $0.60 $0.45
Weighted Average Diluted Shares Outstanding
- - 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B
Weighted Average Basic & Diluted Shares Outstanding
- - 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B

Quarterly Income Statements for Takeda Pharmaceutical

No quarterly income statements for Takeda Pharmaceutical are available.


Annual Cash Flow Statements for Takeda Pharmaceutical

This table details how cash moves in and out of Takeda Pharmaceutical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Net Change in Cash & Equivalents
-938 -392 3,943 -404 2,858 -1,196 -2,554 -674 -409
Net Cash From Operating Activities
2,346 3,555 -2,950 6,250 9,139 9,248 7,361 4,737 7,053
Net Cash From Continuing Operating Activities
2,346 3,555 2,950 6,182 11,218 9,313 7,412 4,789 7,121
Net Income / (Loss) Continuing Operations
1,037 1,757 1,213 413 3,401 1,895 2,388 954 721
Consolidated Net Income / (Loss)
1,037 1,757 1,213 413 3,401 1,895 2,388 954 721
Depreciation Expense
1,539 1,714 2,225 5,446 5,059 4,802 5,005 4,814 5,079
Non-Cash Adjustments To Reconcile Net Income
-241 44 -36 2,325 1,837 2,023 1,842 2,705 2,340
Changes in Operating Assets and Liabilities, net
11 41 -451 -2,003 922 593 -1,823 -3,683 -1,020
Net Cash From Investing Activities
-5,887 -878 -25,467 2,726 3,557 -1,631 -4,573 -3,067 -2,449
Net Cash From Continuing Investing Activities
-5,887 -878 -25,465 2,726 3,557 -1,631 -4,573 -2,847 -2,522
Purchase of Property, Plant & Equipment
-1,006 -1,207 -1,204 -2,032 -2,138 -1,532 -4,774 -3,179 -2,320
Purchase of Investments
-109 -834 -154 -70 -114 -69 -76 -45 -651
Sale of Property, Plant & Equipment
24 28 455 117 420 15 7.25 57 0.52
Divestitures
578 800 765 4,307 4,795 232 60 132 137
Sale and/or Maturity of Investments
98 478 665 581 688 191 233 214 318
Other Investing Activities, net
-183 122 577 -132 -93 -60 -23 -26 -7.41
Net Cash From Financing Activities
2,603 -3,069 26,460 -9,380 -9,839 -8,813 -5,342 -2,344 -5,013
Net Cash From Continuing Financing Activities
2,603 -3,069 26,460 -9,380 -9,839 -8,813 -5,342 -2,741 -5,326
Repayment of Debt
-1,820 -5,221 2,794 -11,286 -17,604 -7,889 -3,530 -1,315 -9,685
Repurchase of Common Equity
-208 -176 0.00 -35 -334 -638 -203 -15 -346
Payment of Dividends
-1,272 -1,335 -1,284 -2,637 -2,562 -2,336 -2,105 -1,899 -2,018
Issuance of Debt
5,990 3,702 25,110 4,630 10,663 2,053 565 661 6,834
Other Financing Activities, net
-88 -38 -150 -52 -1.55 -3.17 -69 -173 -111

Quarterly Cash Flow Statements for Takeda Pharmaceutical

No quarterly cash flow statements for Takeda Pharmaceutical are available.


Annual Balance Sheets for Takeda Pharmaceutical

This table presents Takeda Pharmaceutical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Total Assets
38,636 123,873 119,640 116,726 108,515 105,143 99,913 95,052
Total Current Assets
10,150 26,880 23,044 24,524 21,357 18,064 16,920 16,819
Cash & Equivalents
2,771 6,305 5,950 8,735 6,997 4,019 3,027 2,569
Accounts Receivable
3,954 6,663 7,064 7,079 5,737 4,892 4,420 4,733
Inventories, net
2,041 12,653 8,556 7,002 7,025 7,546 8,062 8,210
Current Deferred & Refundable Income Taxes
80 65 260 268 228 243 193 105
Other Current Assets
1,304 1,194 1,213 1,441 1,370 1,364 1,217 1,201
Plant, Property, & Equipment, net
5,051 11,962 12,937 13,143 13,034 12,740 13,158 13,130
Plant, Property & Equipment, gross
5,051 11,962 12,937 13,143 13,034 12,740 13,158 13,130
Total Noncurrent Assets
23,435 85,030 83,660 79,058 74,124 74,339 69,835 65,103
Long-Term Investments
1,016 972 1,002 3,149 2,718 2,854 2,848 2,414
Goodwill
9,684 38,082 37,443 36,466 36,296 36,088 35,776 35,520
Intangible Assets
9,543 42,670 38,925 35,338 31,444 32,163 28,268 24,227
Noncurrent Deferred & Refundable Income Taxes
611 799 2,875 3,198 2,985 2,757 2,605 2,473
Other Noncurrent Operating Assets
2,582 2,508 3,415 907 680 477 339 469
Total Liabilities & Shareholders' Equity
38,636 123,873 119,640 116,726 108,515 105,143 99,913 95,052
Total Liabilities
19,655 77,297 75,526 69,924 61,714 57,274 51,811 48,782
Total Current Liabilities
6,939 22,929 20,304 16,029 17,669 18,696 15,296 16,721
Short-Term Debt
0.17 8,846 5,476 200 1,680 2,558 2,429 3,662
Accounts Payable
2,260 2,940 2,975 3,108 4,251 4,891 3,621 3,172
Current Deferred & Payable Income Tax Liabilities
637 1,353 1,705 1,313 1,654 1,750 727 891
Other Current Liabilities
3,763 9,365 9,255 11,408 10,083 9,497 8,520 8,996
Total Noncurrent Liabilities
12,716 54,368 55,221 53,895 44,044 38,577 36,514 32,060
Long-Term Debt
9,274 42,803 42,052 41,703 34,103 30,454 29,603 26,460
Noncurrent Deferred & Payable Income Tax Liabilities
854 7,035 7,139 5,212 3,896 2,224 781 237
Noncurrent Employee Benefit Liabilities
824 1,406 1,461 1,436 1,201 961 951 903
Other Noncurrent Operating Liabilities
1,765 3,124 4,568 5,544 4,845 4,939 5,179 4,460
Total Equity & Noncontrolling Interests
18,981 46,575 44,115 46,801 46,801 47,869 48,102 46,271
Total Preferred & Common Equity
18,793 46,539 44,077 46,764 46,797 47,865 48,097 46,265
Preferred Stock
854 14,821 15,680 15,263 14,072 13,023 11,555 11,846
Total Common Equity
17,939 31,719 28,398 31,500 32,725 34,842 36,542 34,419
Common Stock
733 14,761 15,566 15,080 13,803 12,628 11,087 11,305
Retained Earnings
14,652 14,329 12,784 13,649 12,185 11,609 9,200 7,923
Treasury Stock
-700 -513 -816 -538 -955 -756 -339 -499
Other Equity Adjustments
3,299 3,142 864 3,310 7,692 11,361 16,594 15,690
Noncontrolling Interest
188 36 37 37 4.15 4.14 4.90 5.97

Quarterly Balance Sheets for Takeda Pharmaceutical

No quarterly balance sheets for Takeda Pharmaceutical are available.


Annual Metrics And Ratios for Takeda Pharmaceutical

This table displays calculated financial ratios and metrics derived from Takeda Pharmaceutical's official financial filings.

Metric 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 3/31/2017 3/31/2018 3/31/2019 3/31/2020 3/31/2021 3/31/2022 3/31/2023 3/31/2024 3/31/2025
Growth Metrics
- - - - - - - - -
Revenue Growth
0.00% 7.13% 13.07% 63.06% -5.87% 1.66% 3.23% -7.06% 8.40%
EBITDA Growth
0.00% 26.02% 7.65% 55.25% 56.89% -12.35% 1.94% -27.36% 16.99%
EBIT Growth
0.00% 42.33% -11.62% -59.08% 545.67% -20.33% -1.05% -59.82% 54.88%
NOPAT Growth
0.00% 73.41% 15.55% -70.97% 620.97% -38.95% 8.19% 23.81% -63.49%
Net Income Growth
0.00% 69.39% -30.94% -65.93% 722.79% -44.26% 26.01% -60.07% -24.34%
EPS Growth
0.00% 62.42% -41.14% -79.80% 745.88% -99.50% 26.64% -60.37% -25.60%
Operating Cash Flow Growth
0.00% 51.51% -182.98% 311.85% 46.22% 1.20% -20.41% -35.64% 48.88%
Free Cash Flow Firm Growth
0.00% 0.00% -182.41% 110.01% 109.43% -49.31% -71.01% 82.42% 17.81%
Invested Capital Growth
0.00% 0.00% 269.23% -6.33% -10.24% -5.15% 1.56% 0.34% -3.84%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics
- - - - - - - - -
Gross Margin
67.74% 71.99% 68.92% 66.89% 68.91% 68.99% 69.11% 66.54% 65.51%
EBITDA Margin
18.81% 22.12% 21.06% 20.06% 33.43% 28.82% 28.46% 22.25% 24.01%
Operating Margin
9.00% 13.66% 11.33% 3.05% 15.93% 12.91% 12.18% 5.02% 7.48%
EBIT Margin
8.91% 11.84% 9.25% 2.32% 15.93% 12.48% 11.96% 5.17% 7.39%
Profit (Net Income) Margin
6.67% 10.55% 6.44% 1.35% 11.76% 6.45% 7.87% 3.38% 2.36%
Tax Burden Percent
80.58% 85.96% 105.85% -72.90% 102.71% 76.07% 84.52% 273.15% 61.77%
Interest Burden Percent
92.89% 103.63% 65.76% -79.50% 71.90% 67.92% 77.84% 23.94% 51.71%
Effective Tax Rate
19.42% 14.04% -5.85% 0.00% -2.71% 23.93% 15.48% -173.15% 38.23%
Return on Invested Capital (ROIC)
0.00% 15.80% 3.89% 0.74% 5.82% 3.86% 4.25% 5.22% 1.94%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 8.91% -0.25% 0.18% 2.11% 0.32% 1.44% -5.93% -0.75%
Return on Net Nonoperating Assets (RNNOA)
0.00% 2.71% -0.19% 0.17% 1.66% 0.19% 0.79% -3.23% -0.41%
Return on Equity (ROE)
0.00% 18.51% 3.70% 0.91% 7.48% 4.05% 5.05% 1.99% 1.53%
Cash Return on Invested Capital (CROIC)
0.00% -184.20% -110.86% 7.28% 16.62% 9.14% 2.70% 4.88% 5.85%
Operating Return on Assets (OROA)
0.00% 5.10% 2.14% 0.59% 3.90% 3.26% 3.40% 1.42% 2.32%
Return on Assets (ROA)
0.00% 4.55% 1.49% 0.34% 2.88% 1.68% 2.24% 0.93% 0.74%
Return on Common Equity (ROCE)
0.00% 17.49% 2.80% 0.60% 4.93% 2.78% 3.60% 1.48% 1.15%
Return on Equity Simple (ROE_SIMPLE)
0.00% 9.35% 2.61% 0.94% 7.27% 4.05% 4.99% 1.98% 1.56%
Net Operating Profit after Tax (NOPAT)
1,128 1,955 2,260 656 4,729 2,887 3,123 3,867 1,412
NOPAT Margin
7.25% 11.74% 12.00% 2.14% 16.36% 9.82% 10.29% 13.71% 4.62%
Net Nonoperating Expense Percent (NNEP)
0.00% 6.90% 4.14% 0.56% 3.72% 3.54% 2.82% 11.14% 2.69%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 1.85%
Cost of Revenue to Revenue
32.26% 28.01% 31.08% 33.11% 31.09% 31.01% 30.89% 33.46% 34.49%
SG&A Expenses to Revenue
35.74% 35.48% 34.22% 29.31% 27.38% 24.84% 24.76% 24.72% 24.11%
R&D to Revenue
18.03% 18.38% 17.56% 14.96% 14.25% 14.74% 15.73% 17.12% 15.94%
Operating Expenses to Revenue
58.74% 58.33% 57.59% 63.84% 52.98% 56.07% 56.93% 61.52% 58.03%
Earnings before Interest and Taxes (EBIT)
1,385 1,972 1,743 713 4,604 3,668 3,630 1,458 2,259
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
2,925 3,685 3,967 6,159 9,664 8,470 8,635 6,273 7,338
Valuation Ratios
- - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 0.00 0.80 0.90 0.75 0.79 0.64 0.73
Price to Tangible Book Value (P/TBV)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.74 0.98 0.84 0.91 0.83 0.82
Price to Earnings (P/E)
0.00 0.00 0.00 55.02 8.37 13.01 11.50 24.70 34.89
Dividend Yield
0.00% 0.00% 2.25% 5.72% 4.58% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 1.82% 11.95% 7.69% 8.70% 4.05% 2.87%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.92 0.96 0.89 0.90 0.82 0.87
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 2.57 2.55 2.20 2.20 2.17 2.03
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 12.83 7.63 7.65 7.72 9.76 8.46
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 110.79 16.02 17.66 18.35 42.00 27.50
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 120.46 15.60 22.44 21.33 15.84 44.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 12.64 8.07 7.00 9.05 12.93 8.81
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 12.26 5.47 9.47 33.60 16.93 14.58
Leverage & Solvency
- - - - - - - - -
Debt to Equity
0.00 0.49 1.11 1.08 0.90 0.76 0.69 0.67 0.65
Long-Term Debt to Equity
0.00 0.49 0.92 0.95 0.89 0.73 0.64 0.62 0.57
Financial Leverage
0.00 0.30 0.77 0.95 0.79 0.60 0.55 0.54 0.54
Leverage Ratio
0.00 2.04 2.48 2.69 2.60 2.41 2.26 2.14 2.07
Compound Leverage Factor
0.00 2.11 1.63 -2.13 1.87 1.63 1.76 0.51 1.07
Debt to Total Capital
0.00% 32.82% 52.58% 51.86% 47.24% 43.33% 40.82% 39.97% 39.43%
Short-Term Debt to Total Capital
0.00% 0.00% 9.01% 5.98% 0.23% 2.03% 3.16% 3.03% 4.79%
Long-Term Debt to Total Capital
0.00% 32.82% 43.58% 45.89% 47.01% 41.29% 37.65% 36.94% 34.64%
Preferred Equity to Total Capital
0.00% 3.02% 15.09% 17.11% 17.21% 17.04% 16.10% 14.42% 15.51%
Noncontrolling Interests to Total Capital
0.00% 0.67% 0.04% 0.04% 0.04% 0.01% 0.01% 0.01% 0.01%
Common Equity to Total Capital
0.00% 63.49% 32.29% 30.99% 35.51% 39.63% 43.08% 45.60% 45.06%
Debt to EBITDA
0.00 2.52 13.02 7.72 4.34 4.22 3.82 5.11 4.10
Net Debt to EBITDA
0.00 1.49 11.18 6.59 3.11 3.08 3.03 4.17 3.43
Long-Term Debt to EBITDA
0.00 2.52 10.79 6.83 4.32 4.03 3.53 4.72 3.61
Debt to NOPAT
0.00 4.74 22.86 72.47 8.86 12.40 10.57 8.28 21.34
Net Debt to NOPAT
0.00 2.81 19.64 61.87 6.35 9.03 8.37 6.76 17.81
Long-Term Debt to NOPAT
0.00 4.74 18.94 64.12 8.82 11.81 9.75 7.66 18.74
Altman Z-Score
0.00 0.00 0.00 0.63 0.87 0.82 0.84 0.75 0.83
Noncontrolling Interest Sharing Ratio
0.00% 5.49% 24.25% 33.71% 34.12% 31.38% 28.63% 25.62% 24.81%
Liquidity Ratios
- - - - - - - - -
Current Ratio
0.00 1.46 1.17 1.13 1.53 1.21 0.97 1.11 1.01
Quick Ratio
0.00 0.97 0.57 0.64 0.99 0.72 0.48 0.49 0.44
Cash Flow Metrics
- - - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -22,791 -64,365 6,442 13,493 6,839 1,983 3,617 4,261
Operating Cash Flow to CapEx
238.91% 301.57% -393.87% 326.50% 532.03% 609.65% 154.44% 151.73% 304.00%
Free Cash Flow to Firm to Interest Expense
0.00 -75.87 -86.05 4.18 6.00 4.99 1.55 2.49 3.04
Operating Cash Flow to Interest Expense
11.24 11.83 -3.94 4.06 4.07 6.74 5.76 3.26 5.03
Operating Cash Flow Less CapEx to Interest Expense
6.54 7.91 -4.95 2.82 3.30 5.64 2.03 1.11 3.38
Efficiency Ratios
- - - - - - - - -
Asset Turnover
0.00 0.43 0.23 0.25 0.24 0.26 0.28 0.28 0.31
Accounts Receivable Turnover
0.00 4.21 3.55 4.47 4.09 4.59 5.71 6.06 6.68
Inventory Turnover
0.00 2.29 0.80 0.96 1.16 1.30 1.29 1.21 1.30
Fixed Asset Turnover
0.00 3.30 2.21 2.47 2.22 2.25 2.35 2.18 2.33
Accounts Payable Turnover
0.00 2.06 2.25 3.44 2.96 2.48 2.05 2.22 3.10
Days Sales Outstanding (DSO)
0.00 86.64 102.87 81.57 89.29 79.58 63.94 60.27 54.65
Days Inventory Outstanding (DIO)
0.00 159.67 458.16 380.63 315.89 280.88 283.76 301.92 281.72
Days Payable Outstanding (DPO)
0.00 176.83 162.16 106.16 123.51 147.37 178.03 164.64 117.60
Cash Conversion Cycle (CCC)
0.00 69.47 398.87 356.04 281.66 213.09 169.66 197.56 218.77
Capital & Investment Metrics
- - - - - - - - -
Invested Capital
0.00 24,747 91,371 85,585 76,821 72,868 74,008 74,258 71,409
Invested Capital Turnover
0.00 1.35 0.32 0.35 0.36 0.39 0.41 0.38 0.42
Increase / (Decrease) in Invested Capital
0.00 24,747 66,625 -5,787 -8,764 -3,953 1,140 250 -2,849
Enterprise Value (EV)
0.00 0.00 0.00 79,009 73,765 64,780 66,624 61,249 62,108
Market Capitalization
0.00 0.00 0.00 22,715 28,445 24,637 27,457 23,532 25,118
Book Value per Share
$0.00 $0.00 $20.27 $18.15 $20.22 $19.02 $20.91 $21.57 $20.38
Tangible Book Value per Share
$0.00 $0.00 ($31.33) ($30.65) ($25.87) ($20.35) ($20.05) ($16.23) ($14.99)
Total Capital
0.00 28,255 98,224 91,643 88,704 82,583 80,881 80,133 76,393
Total Debt
0.00 9,274 51,649 47,528 41,903 35,782 33,012 32,031 30,122
Total Long-Term Debt
0.00 9,274 42,803 42,052 41,703 34,103 30,454 29,603 26,460
Net Debt
0.00 5,487 44,372 40,577 30,020 26,067 26,139 26,156 25,138
Capital Expenditures (CapEx)
982 1,179 749 1,914 1,718 1,517 4,766 3,122 2,320
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 440 6,492 2,265 -39 -1,629 -2,094 1,025 1,191
Debt-free Net Working Capital (DFNWC)
0.00 3,211 12,797 8,215 8,695 5,368 1,926 4,052 3,760
Net Working Capital (NWC)
0.00 3,211 3,952 2,739 8,495 3,688 -633 1,623 98
Net Nonoperating Expense (NNE)
91 199 1,046 243 1,328 991 735 2,913 690
Net Nonoperating Obligations (NNO)
0.00 5,766 44,796 41,470 30,020 26,067 26,139 26,156 25,138
Total Depreciation and Amortization (D&A)
1,539 1,714 2,225 5,446 5,059 4,802 5,005 4,814 5,079
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 2.64% 34.47% 7.38% -0.14% -5.54% -6.90% 3.63% 3.90%
Debt-free Net Working Capital to Revenue
0.00% 19.28% 67.94% 26.75% 30.08% 18.27% 6.35% 14.37% 12.30%
Net Working Capital to Revenue
0.00% 19.28% 20.98% 8.92% 29.39% 12.55% -2.09% 5.76% 0.32%
Earnings Adjustments
- - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $113.50 $28.41 $240.72 $147.14 $204.29 $0.61 $0.46
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B
Adjusted Diluted Earnings per Share
$0.00 $0.00 $112.86 $28.25 $238.96 $145.87 $201.94 $0.60 $0.45
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 1.57B 1.56B 1.72B 1.67B 1.69B 1.69B 1.70B
Normalized Net Operating Profit after Tax (NOPAT)
1,655 2,979 2,143 2,280 4,861 3,883 4,048 1,947 2,263
Normalized NOPAT Margin
10.64% 17.88% 11.38% 7.43% 16.82% 13.21% 13.34% 6.91% 7.41%
Pre Tax Income Margin
8.28% 12.27% 6.08% -1.85% 11.45% 8.48% 9.31% 1.24% 3.82%
Debt Service Ratios
- - - - - - - - -
EBIT to Interest Expense
6.64 6.56 2.33 0.46 2.05 2.67 2.84 1.00 1.61
NOPAT to Interest Expense
5.40 6.51 3.02 0.43 2.10 2.10 2.44 2.66 1.01
EBIT Less CapEx to Interest Expense
1.93 2.64 1.33 -0.78 1.28 1.57 -0.89 -1.14 -0.04
NOPAT Less CapEx to Interest Expense
0.70 2.59 2.02 -0.82 1.34 1.00 -1.29 0.51 -0.65
Payout Ratios
- - - - - - - - -
Dividend Payout Ratio
122.66% 76.00% 105.83% 638.03% 75.33% 123.24% 88.13% 199.16% 279.72%
Augmented Payout Ratio
142.67% 86.04% 105.83% 646.46% 85.15% 156.93% 96.63% 200.78% 327.68%

Quarterly Metrics And Ratios for Takeda Pharmaceutical

No quarterly metrics and ratios for Takeda Pharmaceutical are available.


Frequently Asked Questions About Takeda Pharmaceutical's Financials

When does Takeda Pharmaceutical's financial year end?

According to the most recent income statement we have on file, Takeda Pharmaceutical's fiscal year ends in March. Their fiscal year 2025 ended on March 31, 2025.

How has Takeda Pharmaceutical's net income changed over the last 8 years?
The last 5 years of Takeda Pharmaceutical's net income performance:
  • 2021: $3.40 billion
  • 2022: $1.90 billion
  • 2023: $2.39 billion
  • 2024: $953.56 million
  • 2025: $721.43 million
Find out what analysts predict for Takeda Pharmaceutical in the coming months.
What is Takeda Pharmaceutical's operating income?
Takeda Pharmaceutical's total operating income in 2025 was $2.29 billion, based on the following breakdown:
  • Total Gross Profit: $20.02 billion
  • Total Operating Expenses: $17.74 billion
How has Takeda Pharmaceutical's revenue changed over the last 8 years?

Over the last 8 years, Takeda Pharmaceutical's total revenue changed from $15.55 billion in 2017 to $30.56 billion in 2025, a change of 96.6%.

How much debt does Takeda Pharmaceutical have?

Takeda Pharmaceutical's total liabilities were at $48.78 billion at the end of 2025, a 5.8% decrease from 2024, and a 148.2% increase since 2018.

How much cash does Takeda Pharmaceutical have?

In the past 7 years, Takeda Pharmaceutical's cash and equivalents has ranged from $2.57 billion in 2025 to $8.73 billion in 2021, and is currently $2.57 billion as of their latest financial filing in 2025.

How has Takeda Pharmaceutical's book value per share changed over the last 8 years?

Over the last 8 years, Takeda Pharmaceutical's book value per share changed from 0.00 in 2017 to 20.38 in 2025, a change of 2,037.6%.



This page (NYSE:TAK) was last updated on 8/23/2025 by MarketBeat.com Staff
From Our Partners